Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
12 hedge funds and large institutions have $444K invested in Immune Pharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
33% less funds holding
Funds holding: 18 → 12 (-6)
68% less capital invested
Capital invested by funds: $1.41M → $444K (-$964K)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$26.3K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.46K |
| 4 |
Morgan Stanley
New York
|
+$2 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$215K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$188K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$110K |
| 4 |
Goldman Sachs
New York
|
-$33K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.83K |
IMNP Hedge Fund Activity: Q3 2017 in Review
12 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q3 2017, worth a combined $444K — down 68% from $1.41M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMNP and 1 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Two Sigma Securities, adding an estimated $26.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $215K sold.
- 12 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q3 2017, down from 18 in Q2 2017.
- Funds reported $444K of Immune Pharmaceuticals Inc. stock for Q3 2017, down 68% quarter-over-quarter.
- 1 fund opened new Immune Pharmaceuticals Inc. positions in Q3 2017 and 7 closed out, a net change of -6 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q3 2017 was Two Sigma Securities, an estimated $26.3K added.
- The largest Immune Pharmaceuticals Inc. seller in Q3 2017 was Susquehanna International Group, an estimated $215K sold.
Based on aggregated 13F filings for Q3 2017.